Company
Headquarters: Cranbury, NJ, United States
Founded: February 4, 2002
Employees: 496
CEO: Mr. John F. Crowley
$1.83 Billion
USD as of July 1, 2025
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $309.91 B |
Vertex Pharmaceuticals Incorporated | $117.36 B |
CSL Limited | $95.75 B |
Regeneron Pharmaceuticals, Inc. | $59.14 B |
Marinomed Biotech AG | $58.56 B |
Company | Market Cap (USD) |
---|---|
Lilly | $699.59 B |
Johnson & Johnson | $374.29 B |
AbbVie | $336.94 B |
Novo Nordisk | $309.91 B |
UnitedHealth Group | $279.90 B |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Last Financial Reports Date | March 31, 2025 |
Revenue TTM | $543.1 M |
EBITDA | $38.6 M |
Gross Profit TTM | $492.1 M |
Profit Margin | -5.41% |
Operating Margin | -6.35% |
Quarterly Revenue Growth | 13.40% |
Amicus Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: FOLD wb_incandescent
Stock: BMV: FOLD wb_incandescent
Stock: FSX: AM6 wb_incandescent
John Crowley (Chairman and Chief Executive Officer) Bradley Campbell (President and Chief Operating Officer) Daphne Quimi (Chief Financial Officer) David Clark (Chief People Officer)